

References

Key Findings in AML: An Overview with Naval Daver, MD

References

1. Konopleva M, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. *Cancer Discov.* 2016; 6(10):1106-1117.
2. DiNardo CD, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol.* 2018;19(2):216-228.
3. DiNardo CD, Pratz K, Potluri J, et al. Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia (AML). EHA 2018. Abstract: S1563.
https://learningcenter.ehaweb.org/eha/2018/stockholm/214482/courtney.d.dinardo.durable.response.with.venetoclax.in.combination.with.html?f=ce_id=1346*ot_id=19045*media=3
4. Cortes J, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2018;19(7):889-903.
5. Perl AE, Altman JK, Cortes JE, et al. Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). *Blood.* 2016;128:1069.
6. Perl AE, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. *Lancet Oncol.* 2017;18(8):1061-1075.
7. Cortes JC, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication-mutated (MUT) relapsed/refractory AML in the phase 3, randomized, controlled QUANTUM-R trial. Presented at: 2018 EHA Congress; June 14-17, 2018; Stockholm, Sweden. Abstract LB2600.
8. DiNardo CD, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *N Engl J Med.* 2018;378(25):2386-2398.
9. Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. *Blood.* 2017;130(6):722-731.
10. Williams P, et al. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. *J Clin Oncol.* 2018;36(suppl; abstr 7016).
11. Kadia T, Cortes JE, Ghorab A, et al. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. *J Clin Oncol.* 2018;36(suppl; abstr 7014).
12. Daver N, et al. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML. *Blood.* 2017;130:1345.



Abstracts

New Data from the Ongoing Phase 1 Study Evaluating Single-Agent IDH1 Inhibitor AG-120 in Relapsed/Refractory AML with Eunice S. Wang, MD

Pollyea D, DiNardo C, de Botton S, et al. Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. ASCO 2018. Abstract 7000.

<https://meetinglibrary.asco.org/record/161682/abstract>

Swaminathan M, Jabbour E, Ravandi F, et al. Association of early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) with high response rates and long duration of response. ASCO 2018. Abstract 7001.

<https://meetinglibrary.asco.org/record/161754/abstract>

Two Phase 3 Trials in Progress: HDAC Inhibitor Pracinostat in Combination with Azacitidine; NEDD Inhibitor Pevonedistat + Aza with Guillermo Garcia-Manero, MD

Garcia-Manero G, Fong CY, Venditti A, et al. A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC) ASCO 2018. Abstract TPS7078.

<https://meetinglibrary.asco.org/record/165456/abstract>

Sekeres M, Fram R, Hua Z, et al. Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML) ASCO 2018. Abstract TPS7077.

<https://meetinglibrary.asco.org/record/165469/abstract>

Post hoc Analysis of Clinical Activity of Quizartinib in Patients with Prior TKIs with Mark J. Levis, MD, PhD

Levis M, Smith C, Ishizuka K, et al. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. ASCO 2018. Abstract 7017.

<https://meetinglibrary.asco.org/record/162108/abstract>

IDH1 and IDH2 Inhibitors in Combination with Aza in the Upfront Setting *with Richard Stone, MD*

Stein E, DiNardo C, Jang JH, et al. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. ASCO 2018. Abstract TPS7074.

<https://meetinglibrary.asco.org/record/165530/abstract>

DiNardo C, Stein A, Stein E, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). ASCO 2018. Abstract 7042.

<https://meetinglibrary.asco.org/record/162432/abstract>

The Role of Nivolumab in Maintenance Therapy; BCL-2 Inhibitor Studies in Newly Diagnosed AML; Impact of NGS on Therapy Selection *with Naval Dauer, MD*

Kadia T, Cortes J, Ghorab A, et al. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. ASCO 2018. Abstract 7014.

<https://meetinglibrary.asco.org/record/161935/abstract>

DiNardo C, Pratz K, Potluri J, et al. Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia (AML). ASCO 2018. Abstract 7010.

<https://meetinglibrary.asco.org/record/161511/abstract>

Assi R, Pierola A, Devendra KC, et al. Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). ASCO 2018. Abstract 103.

<https://meetinglibrary.asco.org/record/161543/abstract>